The study highlights how macrophages residing in TLS are not merely bystanders within the tumor microenvironment but are crucial orchestrators of immune responses, capable of inducing apoptosis in cancer cells through specific cytokines. IL-18, a pro-inflammatory cytokine, plays a fundamental role in the activation of immune cells, particularly T-cells and natural killer cells. Understanding the mechanisms through which these macrophages can induce apoptosis in cancer cells provides critical insights into the immune system’s potential to combat tumor progression.

Macrophages are a heterogeneous population of immune cells with varying functions depending on their microenvironment and activation state. In the context of TLS, macrophages exhibit a unique phenotype that enhances their ability to interact with cancer cells. The research indicates that macrophages in these structures secrete IL-18, which triggers apoptotic pathways in ATF4-positive gastric cancer cells. This discovery not only emphasizes the importance of macrophages in immune surveillance but also points to the potential for harnessing their capabilities for cancer immunotherapy.

ATF4, a key regulator of the cellular stress response, is upregulated in many cancer types, contributing to cell survival and proliferation. However, the study demonstrates that IL-18 signaling can disrupt this survival mechanism, leading to apoptosis of ATF4-positive cells. This finding is particularly relevant for gastric cancer, which often evades immune detection and promotes tumor growth. The ability of TLS-associated macrophages to target these cancer cells represents a promising strategy for enhancing the efficacy of existing treatments.

Additionally, the interaction between macrophages and cancer cells within TLS raises questions about the broader implications of the tumor microenvironment on immune responses. The study suggests that the spatial arrangement of immune cells within TLS could influence their functional roles, potentially leading to more effective anti-tumor responses. This insight may inform the design of combination therapies that leverage the immune system’s capacity to recognize and eliminate cancer cells.

The research further underscores the need for continued exploration of the cytokine milieu present within TLS. While IL-18 is identified as a key player in this study, the roles of other cytokines in modulating macrophage function and promoting apoptosis deserve further investigation. A comprehensive understanding of these pathways could reveal novel therapeutic targets to enhance the efficacy of existing cancer treatments.

As the medical community continues to explore the intricacies of the immune response to cancer, findings such as those from Zhou et al. stress the importance of interdisciplinary approaches that combine immunology, oncology, and molecular biology. By integrating these fields, researchers can develop more nuanced strategies that not only disrupt tumor growth but also promote the immune system’s capacity to destroy cancer cells.

The potential implications of this research extend beyond gastric cancer alone. Similar mechanisms may be at play in other malignancies characterized by the presence of TLS and macrophages. Investigating these relationships could lead to the identification of common therapeutic targets across various types of cancer, potentially transforming how cancers are approached and treated.

Publications highlighting such profound findings play an essential role in disseminating knowledge across the scientific community. The study by Zhou et al. is likely to encourage further research into the roles of immune cells within the tumor microenvironment, inspiring the next generation of therapeutic strategies designed to manipulate these interactions for better outcomes in cancer patients.

Ultimately, the journey towards understanding and overcoming cancer is a collective effort, requiring collaboration and innovation across disciplines. The promising findings related to macrophages in tertiary lymphoid structures represent a step forward in deciphering the mechanisms of tumor immunology. Ongoing research in this area will not only enhance our understanding of cancer biology but also guide the development of more effective, targeted therapies for patients battling this devastating disease.

The impact of this research on future therapies is significant. It raises critical questions about the potential for clinical applications, such as incorporating IL-18-based treatments or enhancing the infiltration of macrophages into tumors. By focusing on the immune landscape of gastric cancer, researchers could significantly improve survival rates and quality of life for patients.

In conclusion, the study by Zhou et al. offers groundbreaking insights into the relationship between macrophages in tertiary lymphoid structures and gastric cancer cell apoptosis. By elucidating the mechanisms at play, this research not only advances our understanding of cancer immunology but also sets the stage for future therapeutic strategies that can harness the body’s immune response to fight cancer more effectively. As the field continues to evolve, such innovations will remain pivotal in the ongoing battle against cancer, providing hope for improved treatment outcomes in the years to come.

Subject of Research: The role of macrophages in tertiary lymphoid structures and their ability to induce apoptosis in ATF4-positive gastric cancer cells via IL-18 signaling.

Article Title: Macrophages in tertiary lymphoid structures promote apoptosis of ATF4-positive gastric cancer cells via IL-18.

Article References:

Zhou, L., Li, X., Wu, J. et al. Macrophages in tertiary lymphoid structures promote apoptosis of ATF4-positive gastric cancer cells via IL18.
J Transl Med (2025). https://doi.org/10.1186/s12967-025-07559-z

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07559-z

Keywords: macrophages, tertiary lymphoid structures, gastric cancer, apoptosis, IL-18, tumor microenvironment, cytokines, immunotherapy.

CDC6 is fundamentally recognized as an essential factor in the initiation of DNA replication during the G1 and S phases of the cell cycle. Its canonical function involves licensing DNA replication origins, thereby ensuring the fidelity of DNA duplication. However, beyond this classical role, CDC6 is integral to the maintenance of the S-M checkpoint, a critical control mechanism that preserves genomic integrity by preventing premature mitotic entry. Disruptions in CDC6 expression have been implicated in genomic instability, a hallmark of cancer, which underpins its emerging role in tumorigenesis.

This comprehensive pan-cancer analysis leveraged an impressive array of multi-omics data sourced from high-quality repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), cBioPortal, and several others. By integrating genomic, transcriptomic, epigenetic, and proteomic datasets, researchers systematically evaluated CDC6’s expression patterns, mutational status, and epigenetic modifications across a spectrum of malignancies. This multi-dimensional bioinformatics approach allowed for unprecedented insights into CDC6’s oncogenic potential.

One of the groundbreaking findings from this study is the consistent overexpression of CDC6 across a wide range of tumor types when compared to normal tissue counterparts. This upregulation was not merely a passenger event but demonstrated strong associations with adverse clinical prognoses. Such robust correlations were evident in cancers of the lung, breast, colorectal, and notably, melanoma, suggesting that CDC6 could serve as a universal marker for tumor aggressiveness and patient outcomes.

Beyond expression, the investigation delved into the mutational landscape and epigenetic regulation influencing CDC6 activity. Intriguingly, alterations in DNA methylation patterns correlated substantially with shifts in CDC6 expression in nine different cancer types. These epigenetic modifications could provide a mechanistic explanation for the dysregulation of CDC6 and highlight potential avenues for targeted epigenetic therapy.

Equally compelling is the study’s exploration of CDC6’s interaction with the tumor immune microenvironment (TIME). CDC6 expression displayed significant correlation with immune cell infiltration patterns, implicating it in immunomodulation within tumors. These findings underscore CDC6’s dualistic role—not only driving cellular proliferation but also potentially shaping immune evasion or response mechanisms, positioning it as a candidate predictive biomarker for immunotherapy response.

To validate computational findings, the study incorporated functional assays focusing on melanoma, a notoriously aggressive and treatment-resistant skin cancer. Experimental overexpression of CDC6 in melanoma cells led to marked increases in proliferation, migration, and invasive capabilities. These in vitro results confirm CDC6’s critical role in enhancing malignancy and suggest that targeting CDC6 could restrain melanoma progression.

The implications of this research extend beyond biological understanding to clinical translation. Identifying CDC6 as a diagnostic and prognostic biomarker equips clinicians with a potential tool for early detection and risk stratification across several cancer types. Moreover, its influence on the immune microenvironment opens a novel frontier for combination therapies that integrate CDC6 inhibition with immunotherapeutic regimens.

This study also raises important questions about the molecular mechanisms through which CDC6 orchestrates these diverse roles. Does CDC6 interact directly with immune signaling pathways, or is its effect mediated through modulation of the tumor’s genetic and epigenetic landscape? Future studies focusing on the mechanistic underpinnings are necessary to harness CDC6’s full therapeutic potential.

From a therapeutic standpoint, targeting CDC6 could disrupt several oncogenic processes simultaneously—impairing cell cycle progression, restoring checkpoint control, and modulating immune responses. Small molecule inhibitors or RNA interference strategies aimed at CDC6 might provide a multi-pronged approach to combat tumors that rely heavily on its overexpression.

The study’s pan-cancer methodology strengthens the generalizability of findings, making CDC6 a prime candidate for broad-spectrum cancer therapies. Furthermore, its expression correlation with poor prognosis highlights its potential utility in personalized medicine frameworks where CDC6 expression levels could guide treatment choices and monitoring.

In the era of immuno-oncology, biomarkers that link cancer proliferation with immune landscape alterations are invaluable. CDC6 fits seamlessly into this paradigm, providing insights into tumor-immune dynamics and offering a biomarker that could refine patient stratification for immunotherapies. As immunotherapies continue to transform oncology, such dual-function biomarkers become increasingly critical.

Additionally, the observed epigenetic alterations associated with CDC6 hint at the plasticity of its regulation, making it amenable to epigenetic drugs. Combining epigenetic modifiers with conventional treatments could synergistically impede CDC6-driven tumor growth and address drug resistance, a major obstacle in current cancer therapy.

The collective evidence solidifies CDC6’s positioning at the crossroads of cell proliferation, genomic stability, and immune regulation. This convergence highlights the importance of integrative, multi-omics research approaches, as exemplified by this study, which unravel complex tumor biology enabling precision oncology advancements.

In summary, CDC6 emerges from this research not merely as a cell cycle participant but as a powerful oncogenic and immunological hub across diverse cancers. Its potential as a diagnostic beacon, prognostic indicator, and therapeutic target makes it a focal point for future cancer research. As scientists embark on elucidating CDC6’s mechanistic pathways, there is optimism that targeting this molecular linchpin could herald novel, more effective cancer interventions.

Subject of Research: Cell Division Cycle 6 (CDC6) as a pan-cancer biomarker for diagnosis, prognosis, and immunomodulation; its functional role in melanoma malignancy.

Article Title: CDC6 as a pan-cancer immunological and prognostic biomarker and its role in suppressing melanoma malignancy.

Article References:
Mo, L., Jia, M., Wu, Q. et al. CDC6 as a pan-cancer immunological and prognostic biomarker and its role in suppressing melanoma malignancy. BMC Cancer 25, 1426 (2025). https://doi.org/10.1186/s12885-025-14782-w

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14782-w

Immunotherapy has transformed cancer treatment by harnessing the power of the immune system, specifically T cells, to attack malignant cells. However, despite remarkable successes in some patients, many do not respond or eventually develop resistance. The recently published study in Theranostics explores one underappreciated culprit behind this resistance: a circulating form of Clever-1 protein that dampens the immune response on a systemic level. This secreted protein disables T cell activation, making tumors invisible to one of the body’s primary defense mechanisms.

Clever-1, previously identified as a receptor on certain immune cells like macrophages, plays a suppressive role within the tumor microenvironment. The novel discovery focuses on sClever-1, which is released into the bloodstream and exerts a far-reaching inhibitory effect on T cells. By binding directly to activated T cells, sClever-1 disrupts their ability to signal and coordinate an effective anti-tumor immune response. This molecular “cloak” aids cancer cells in evading destruction, helping to explain why some tumors remain impervious to current immunotherapies like anti-PD-1 antibodies.

The study’s lead co-author, Professor Shishir Shetty of the University of Birmingham, emphasized the clinical relevance of these findings. He explained that elevated levels of sClever-1 in patients’ blood correlate strongly with resistance to established immunotherapeutic agents. This protein thus serves as both a biomarker for predicting treatment outcomes and a therapeutic target. The investigational antibody bexmarilimab was shown to inhibit the release of sClever-1, effectively lifting the immunosuppressive blockade and restoring T cell function.

Bexmarilimab represents a promising new class of drugs that not only counteract suppressive signals but also reprogram tumor-associated macrophages to support immune activation rather than inhibition. This dual functionality—blocking sClever-1 secretion and revitalizing immune cells—marks a significant advance in combination therapy approaches. Professor Shetty highlighted the potential to identify patients unlikely to benefit from monotherapy immunotherapies and instead offer tailored regimens incorporating bexmarilimab.

The international collaboration drew upon advanced immunological techniques, including plasma analysis from a robust cohort of patients encompassing 138 breast cancer cases, 193 individuals with advanced solid tumours, and 21 healthy donors. This comprehensive comparative analysis revealed markedly higher concentrations of sClever-1 in cancer patients’ circulation, underpinning its role as a systemic modulator of immunity rather than a localized factor confined to the tumor microenvironment.

Dr. Maija Hollmén, senior author from the University of Turku and the InFLAMES Flagship program, reflected on the broader implications of these mechanistic insights. By uncovering how cancer manipulates immune checkpoints at a molecular level through sClever-1 secretion, the research clarifies a key immune evasion strategy. This knowledge not only validates bexmarilimab’s molecular target but also encourages the development of novel agents capable of dismantling similar suppressive pathways.

A particularly striking aspect of the research is the demonstration that inflammatory signals within the tumor microenvironment induce macrophages and other immune cells to release sClever-1. This discovery links the inflammatory milieu of tumors to systemic immunosuppression and provides a mechanistic framework explaining why some tumors are refractory to PD-1 checkpoint inhibitors. It underscores the complexity of immune regulation in cancer and the need for multi-targeted treatment regimens.

The novel recognition that circulating sClever-1 directly binds to activated T cells advances our fundamental understanding of immune biology in cancer. T cells are central to orchestrating cytotoxic responses, and their functional paralysis by sClever-1 represents a critical barrier to effective immunotherapy. This paradigm shifts the focus from solely targeting checkpoints on T cells to also modulating systemic factors that govern T cell competence.

As immunotherapy continues to evolve, these findings highlight the necessity of personalized medicine strategies that incorporate molecular biomarkers like sClever-1. The ability to stratify patients based on their sClever-1 levels could refine treatment decisions, selecting candidates who would benefit from bexmarilimab-inclusive combinations. This precision approach aims to overcome the heterogeneity and complexity of tumor-immune interactions that limit current therapeutic efficacy.

The study’s forthcoming presentation at the 19th International Congress of Immunology (IUIS 2025) promises to ignite widespread interest and foster collaborative efforts to translate these insights into clinical practice. Supported by Faron Pharmaceuticals, which is developing bexmarilimab, the research epitomizes the synergy between academia and industry in accelerating innovation against cancer.

In summary, the identification and characterization of secreted Clever-1 as a systemic immune suppressor heralds a watershed moment in cancer immunotherapy research. By unveiling how sClever-1 impairs T cell activation and contributes to resistance against widely used treatments, the study opens new therapeutic avenues. The investigational antibody bexmarilimab’s capacity to inhibit this suppressive pathway and restore immune function offers hope for improving outcomes in patients with advanced, treatment-resistant cancers.

This pivotal work not only showcases the power of cutting-edge molecular and immunological techniques but also exemplifies the importance of global scientific collaboration. As the fight against cancer intensifies, such detailed mechanistic understanding will be indispensable for designing smarter, more efficacious immunotherapies. With further clinical validation, targeting sClever-1 could become a cornerstone in overcoming the immunotherapy resistance that currently curtails patient survival.

Subject of Research: The role of secreted Clever-1 (sClever-1) in modulating T cell responses and its impact on the efficacy of cancer immunotherapy.

Article Title: Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy

News Publication Date: 23-Jun-2025

Web References:

• https://www.thno.org/v15p7501.htm
• http://dx.doi.org/10.7150/thno.110544

References:
DOI: 10.7150/thno.110544

Keywords:
Immunotherapy, Immunology, Immunological techniques, Cancer

The TCA cycle is a central metabolic pathway that plays a pivotal role in cellular respiration and energy production. However, cancer cells often exhibit altered metabolism, referred to as the Warburg effect, where they rely more on glycolysis for energy production, even in the presence of oxygen. This metabolic shift results in the production of various oncometabolites that can have significant implications for tumor growth and metastasis.

One of the primary oncometabolites discussed in the research is 2-hydroxyglutarate (2-HG), which has gained recognition for its role in driving tumorigenesis in specific types of malignancies, particularly gliomas and acute myeloid leukemia. The study elucidates how the accumulation of 2-HG occurs via mutations in isocitrate dehydrogenase (IDH) enzymes, which leads to profound epigenetic changes and altered transcriptional programs in tumor cells.

Additionally, fumarate and succinate are other notable oncometabolites derived from TCA cycle dysregulation. The research emphasizes how succinate accumulation, primarily associated with hereditary cancer syndromes such as fumarate hydratase deficiency, can reactivate hypoxia-inducible factor (HIF) pathways. This reactivation results in increased angiogenesis and a pro-tumorigenic environment, creating a perfect storm for tumor progression.

As the immune landscape is intricately linked to tumor metabolism, the study makes a compelling case for examining how these oncometabolites influence immune cell function. Whereas traditional views have largely separated cancer biology and immunology, current findings illustrate a much more complex interaction. For instance, elevated levels of certain metabolites can inhibit T cell activation, thus providing tumors with a means of evading immune surveillance.

The implications of altered TCA cycle metabolism extend beyond mere tumor growth. The research showcases how the interplay between oncometabolites and immune cells can dictate therapeutic outcomes. Understanding the metabolic cross-talk in the tumor microenvironment presents new avenues for immunotherapy. The study argues that if we can manipulate these metabolic pathways, it may be possible to enhance the efficacy of existing treatments or even develop novel strategies targeting metabolic vulnerabilities in tumors.

The authors further discuss the emerging therapeutic potential of targeting these oncometabolites in cancer treatment. Inhibitors that specifically target metabolic pathways associated with oncometabolite production are currently in preclinical and clinical development. For instance, IDH inhibitors have shown promise in treating patients with IDH-mutant cancers, effectively reducing 2-HG levels and thereby reverting some of the malignant features induced by the metabolite.

Moreover, the study emphasizes the importance of combining metabolic therapies with immunotherapies, suggesting that a dual-targeted approach may yield synergistic effects. Recent clinical trials have begun to explore this combination, as fostering a more favorable immune environment while simultaneously crippling the tumor’s energetic capabilities could lead to enhanced therapeutic responses.

In addition to pointing toward novel treatment strategies, the insights gleaned from the study encourage a broader reevaluation of cancer metabolism as a critical factor influencing tumor biology. Researchers are now urged to integrate metabolic profiling into routine clinical practice, as it may not only serve as a prognostic biomarker but also inform treatment decisions based on the distinct metabolic vulnerabilities of individual tumors.

As cancer biology continues to evolve, the understanding of TCA cycle-derived oncometabolites will undoubtedly shape future research directions. The intricate relationship between metabolism and immune response underscores a fundamental shift in how cancer is perceived and treated. It’s a clarion call for researchers and clinicians alike to forge new paths that bridge these two critical fields.

The study by Sarkar and colleagues represents a significant contribution to our understanding of cancer metabolism and the immune microenvironment. As awareness grows, the acknowledgment of these metabolic mechanisms may catalyze the development of innovative therapeutic strategies aimed at dismantling the metabolic foundations of cancer. In the coming years, the promise of exploiting oncometabolites for therapeutic gain will likely become more apparent, ushering in a new era of precision oncology.

The exploration of TCA cycle-derived oncometabolites epitomizes the intertwined nature of cancer progression and the immune response, urging a shift in focus towards a combined metabolic and immunological approach in tackling cancer. As the scientific community continues to unravel the complexities of tumor metabolism, it is clear that the road ahead holds great potential for discovering effective and targeted interventions that could transform cancer care for patients around the globe.

Subject of Research: TCA cycle-derived oncometabolites in cancer and the immune microenvironment

Article Title: TCA cycle-derived oncometabolites in cancer and the immune microenvironment

Article References:

Sarkar, S., Chang, CI., Jean, J. et al. TCA cycle-derived oncometabolites in cancer and the immune microenvironment.
J Biomed Sci 32, 87 (2025). https://doi.org/10.1186/s12929-025-01186-y

Image Credits: AI Generated

DOI: 10.1186/s12929-025-01186-y

Keywords: TCA cycle, oncometabolites, cancer metabolism, immune microenvironment, 2-hydroxyglutarate, fumarate, succinate, immunotherapy, metabolic therapy.

Hepatocellular carcinoma remains a formidable clinical challenge, largely due to its complex pathogenesis and the limited effectiveness of existing therapies. The liver’s unique metabolic functions and immunological milieu contribute significantly to the complexity of HCC progression. By delving into the molecular underpinnings of this malignancy, Wang and colleagues aimed to elucidate how RBM17 orchestrates tumor growth and immune modulation, potentially unveiling new angles for intervention.

RBM17 is known to play multifaceted roles in RNA processing, including splicing and stability regulation. However, its involvement in cancer metabolism and immunity had remained elusive until now. Through a series of sophisticated molecular and cellular assays, the research team demonstrated how aberrant expression of RBM17 in hepatocellular carcinoma cells fuels oncogenic processes by reprogramming lipid metabolism pathways, enabling malignant cells to thrive under metabolic stress.

Metabolic reprogramming is a hallmark of cancer, with lipid metabolism increasingly recognized as a pivotal element for tumor development. Dysregulated lipid synthesis and degradation provide cancer cells with essential building blocks for membrane biogenesis and energy production. This study makes a compelling case that RBM17 amplifies these metabolic alterations, creating a feed-forward loop that sustains tumor survival and proliferation.

Beyond metabolism, the study highlights the critical influence of RBM17 on the tumor immune microenvironment (TIME). Tumors are not isolated entities; they interact dynamically with immune cells that can either suppress or promote cancer growth. Wang and colleagues uncovered that RBM17 modulates the infiltration and polarization of immune cell subsets, essentially sculpting an environment that favors immune evasion and tumor progression.

The researchers applied cutting-edge transcriptomic and proteomic analyses on patient-derived HCC samples and experimental models, pinpointing key downstream effectors regulated by RBM17. These downstream molecules govern lipid metabolic enzymes and immunomodulatory factors, which orchestrate the crosstalk between cancer cells and immune components. Decoding these molecular networks paves the way for precision medicine approaches targeting RBM17 and its effectors.

Significantly, the team demonstrated that silencing RBM17 expression in HCC cell lines resulted in impaired tumor growth, diminished lipid metabolic activity, and reinvigoration of anti-tumor immunity. These compelling functional validations underscore RBM17’s potential as a therapeutic target, particularly with strategies aimed at disrupting tumor metabolism and enhancing immune-mediated tumor clearance.

This discovery gains further importance in the context of current immunotherapies. While checkpoint inhibitors have transformed cancer treatment paradigms, their efficacy in HCC is inconsistent, partly due to an immunosuppressive microenvironment. Modulating RBM17 activity could potentially remodel this microenvironment to sensitize tumors to immune checkpoint blockade, offering a dual-pronged attack against cancer cells.

Moreover, the study also explored the regulatory mechanisms controlling RBM17 itself, revealing potential upstream signals and transcription factors that induce its overexpression in hepatocellular carcinoma. Understanding these regulatory axes not only enriches the biological narrative but also identifies additional nodes for therapeutic intervention.

The ramifications of this study transcend hepatocellular carcinoma, as RBM17 is expressed across various cancers. Its dual role in metabolic modulation and immune regulation suggests that RBM17 could be a universal target for multiple malignancies characterized by similar tumor microenvironment dynamics. Future investigations could explore its relevance in other tumor types, widening the impact of this foundational research.

Despite the promise, challenges remain in translating these findings into clinical applications. The development of small-molecule inhibitors or RNA-based therapeutics against RBM17 requires further optimization and rigorous safety evaluations. Furthermore, the complexity of lipid metabolism and immune interactions in vivo necessitates comprehensive preclinical studies to unravel potential off-target effects and resistance mechanisms.

Nevertheless, the insights gleaned by Wang et al. fuel optimism for the next generation of cancer therapies. By targeting fundamental tumor-supportive processes such as lipid metabolism and immune suppression, RBM17-focused interventions might overcome resistance to conventional treatments and deliver durable responses in HCC patients.

This research exemplifies the power of integrative molecular oncology, leveraging multi-omics data, sophisticated bioinformatics, and robust experimental validation. Such multidisciplinary approaches are indispensable in confronting the intricacies of cancer biology and propelling precision oncology toward clinical reality.

In summary, the identification of RBM17 as a master regulator that accelerates hepatocellular carcinoma progression through lipid metabolic reprogramming and immune microenvironment modulation marks a significant advance. This novel understanding invites the scientific and medical communities to develop innovative therapeutic strategies that could dramatically improve outcomes for patients suffering from liver cancer.

As the global burden of HCC continues to rise, insights from studies like this underscore the urgent need for translational research bridging molecular discoveries and patient care. RBM17 stands out as a beacon offering hope for better diagnostics, prognostics, and personalized treatment regimens in hepatocellular carcinoma.

Subject of Research: The role of RBM17 in hepatocellular carcinoma progression, focusing on its regulation of lipid metabolism and the immune microenvironment.

Article Title: RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting.

Article References:
Wang, Z., Liu, J., Lai, Y. et al. RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting. Cell Death Discov. 11, 338 (2025). https://doi.org/10.1038/s41420-025-02642-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02642-2